Browsing Tag
biotech R&D
1 post
AN2 Therapeutics reveals 40% 90-day mortality in NIH-backed melioidosis study, advancing epetraborole toward Phase 2 trial
AN2 Therapeutics reports high 90-day mortality in 200-patient NIH-funded melioidosis study, laying groundwork for Phase 2 epetraborole trial in 2025.